SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy

Ain Shams University

Status: Completed

Conditions: Diabetic Retinopathy

Treatments: Genetic: SLMAP and EPO genetic polymorphism

Study type: Observational

Funder types: Other

Identifiers

NCT05344690

RHDIRB2020110301 REC 72

Details and patient eligibility

About

A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.

Full description

Traditional environmental risk factors, such as glycemic control and duration of diabetes, failed to fully explain why some individuals remain protected while others progress to severe diabetic retinopathy.

Several studies suggest variations in diabetic retinopathy prevalence depending on racial background and genetic polymorphism.

Enrollment: 180 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >30-60
• Type 2 DM
• Duration of diabetes from 5-10 years
• Egyptian patients

Exclusion criteria

• Other ophthalmic diseases not related to diabetes

Trial design

180 participants in 2 patient groups

cases

Description:

diabetic patients suffering from clinically confirmed diabetic retinopathy

Treatment:

Genetic: SLMAP and EPO genetic polymorphism

controls

Description:

matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.

Treatment:

Genetic: SLMAP and EPO genetic polymorphism